Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 7/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE6A | P16499 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3119582 | 0.84 | PDE10A (0.54) | MTHFD2PDE10A | |
| SCHEMBL3122533 | 0.79 | — | — | |
| SCHEMBL15001936 | 0.79 | PDE10A (0.41) | MTHFD2PDE10APDE5APDE6APDE4A | |
| SCHEMBL27007528 | 0.77 | P2RX7 (0.46) | MTHFD2PDE10ATSHR | |
| SCHEMBL3116963 | 0.77 | CYP2C19 (0.41) | MTHFD2PDE10A | |
| SCHEMBL16010695 | 0.75 | KCNK3 (0.50) | PDE10A | |
| SCHEMBL19664912 | 0.75 | TNKS2 (0.51) | — | |
| SCHEMBL25438364 | 0.75 | MTOR (0.48) | PDE10A | |
| SCHEMBL4805235 | 0.74 | LMNA (0.52) | — | |
| SCHEMBL27013361 | 0.74 | LMNA (0.56) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179173-A1 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179173-A1 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR35, GPR55 | MTHFD2 1458/4885PDE10A 2712/4885PDE5A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.